What is claimed is:

1. Use of a compound of Formula (I):



I,

or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating B-cell lymphoma (BCL) in combination with a second therapeutic agent, wherein the second therapeutic agent is a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or an equivalent thereof.

2. The use of claim 1, wherein the BCL is aggressive B-cell lymphoma (a-BCL).

3. The use of claim 2, wherein the a-BCL is diffuse large B-cell lymphoma (DLBCL).

4. The use of claim 3, wherein the DLBCL is DLBCL not otherwise specified (NOS).

5. The use of claim 3 or 4, wherein the DLBCL is germinal center B-cell (GCB) type or activated B-cell (ABC) type.

6. The use of claim 2, wherein the a-BCL is high-grade B-cell lymphoma.

7. The use of claim 6, wherein the high-grade B-cell lymphoma has MYC and BCL2 and/or BCL6 rearrangements.

8. The use of claim 2, wherein the a-BCL is primary mediastinal (thymic) large B-cell lymphoma (PMBCL).

9. The use of claim 2, wherein the a-BCL is primary cutaneous DLBCL-leg type.

10. The use of claim 2, wherein the a-BCL is anaplastic lymphoma kinase positive (ALK+) large B-cell lymphoma.

11. The use of claim 2, wherein the a-BCL is Epstein Barr virus positive (EBV+) DLBCL.

12. The use of claim 11, wherein the EBV+ DLBCL is EBV+ DLBCL not otherwise specified (NOS).

13. The use of claim 2, wherein the a-BCL is Grade 3b follicular lymphoma (FL).

14. The use of claim 2, wherein the a-BCL is T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), intravascular large B-cell lymphoma, plasmablastic lymphoma, or primary effusion lymphoma (PEL).

15. The use of any one of claims 1 to 14, wherein the BCL has International Prognostic Index (IPI) score of 3 to 5.

16. The use of any one of claims 1 to 15, wherein the BCL is previously untreated.

17. The use of any one of claims 1 to 15, wherein the BCL is newly diagnosed.

18. The use of any one of claims 1 to 17, wherein the second therapeutic agent is a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

19. The use of any one of claims 1 to 17, wherein the second therapeutic agent is a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.

20. The use of any one of claims 1 to 19, wherein rituximab, cyclophosphamide, doxorubicin, and vincristine are to be administered on day 1 of a 21-day cycle, and prednisone or an equivalent thereof is to be administered on days 1 to 5 of the 21-day cycle.

21. The use of any one of claims 1 to 20, wherein rituximab is to be administered intravenously or subcutaneously; cyclophosphamide, doxorubicin, and vincristine are to be administered intravenously; and prednisone or an equivalent thereof is to be administered orally.

22. The use of any one of claims 1 to 21, wherein rituximab is to be administered intravenously at a dose of about 375 mg/m^2, or subcutaneously at a dose of about 1400 mg, on day 1 of a 21-day cycle; cyclophosphamide is to be administered intravenously at a dose of about 750 mg/m^2 on day 1 of the 21-day cycle; doxorubicin is to be administered intravenously at a dose of about 50 mg/m^2 on day 1 of the 21-day cycle; vincristine is to be administered intravenously at a dose of about 1.4 mg/m^2 on day 1 of the 21-day cycle; and prednisone or an equivalent thereof is to be administered orally at a dose of about 100 mg on days 1 to 5 of the 21-day cycle.

23. The use of any one of claims 1 to 22, wherein a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is used in the manufacture of the medicament.

24. The use of claim 23, wherein a hydrochloride salt of a compound of Formula (I) is used in the manufacture of the medicament.

25. The use of any one of claims 1 to 24, wherein the medicament is manufactured to be administered orally.

26. The use of any one of claims 1 to 25, wherein the medicament is manufactured for the compound to be administered at a dose of from about 0.2 mg to about 0.6 mg once daily (QD).

27. The use of claim 26, wherein the medicament is manufactured for the compound to be administered at a dose of about 0.2 mg, about 0.4 mg, or about 0.6 mg once daily (QD).

28. The use of any one of claims 1 to 27, wherein the medicament is manufactured to be administered
(a) at a dose of about 0.2 mg QD on days 1 to 7 of a 21-day cycle;

(b) at a dose of about 0.4 mg QD on days 1 to 7 of a 21-day cycle;
(c) at a dose of about 0.4 mg QD on days 1 to 10 of a 21-day cycle; or
(d) at a dose of about 0.6 mg QD on days 1 to 7 of a 21-day cycle.

29. The use of claim 1, for treating a-BCL, wherein (i) the medicament is manufactured to be administered on days 1 to 7 of a 21-day cycle; (ii) rituximab, cyclophosphamide, doxorubicin, and vincristine are to be administered on day 1 of the 21-day cycle; and (iii) prednisone or prednisolone is to be administered on days 1 to 5 of the 21-day cycle.

30. The use of claim 1, for treating a-BCL, wherein (i) the medicament is manufactured to be administered on days 1 to 10 of a 21-day cycle; (ii) rituximab, cyclophosphamide, doxorubicin, and vincristine are to be administered on day 1 of the 21-day cycle; and (iii) prednisone or prednisolone is to be administered on days 1 to 5 of the 21-day cycle.

31. The use of any one of claims 1 to 30, wherein the medicament is manufactured for further combination with granulocyte-colony stimulating factor (G-CSF) or pegylated granulocyte colony stimulating factor (peg-G-CSF).

32. The use of claim 31, wherein G-CSF is to be administered on days 5 to 13 of a 21-day cycle whereas the medicament is manufactured to be administered on days 1 to 7 of the 21-day cycle; or G-CSF is to be administered on days 5 to 13 of a 21-day cycle whereas the medicament is manufactured to be administered on days 1 to 10 of the 21-day cycle.

33. The use of claim 31, wherein peg-G-CSF is to be administered on day 2 of a 21-day cycle whereas the medicament is manufactured to be administered on days 1 to 7 of the 21-day cycle; or peg-G-CSF is to be administered on day 2 of a 21-day cycle whereas the medicament is manufactured to be administered on days 1 to 10 of the 21-day cycle.

34. The use of any one of claims 1 to 33, wherein the medicament, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or an equivalent thereof are to be administered in one or more 21-day cycles.

35. The use of claim 34, wherein the medicament, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or an equivalent thereof are to be administered in six 21-day cycles.